Navigation Links
Advanced Life Sciences Announces Third Quarter 2008 Financial Results
Date:11/6/2008

38,524,972 28,292,150

Period From

Inception

(January 1, 1999)

Through

September 30, 2008

Revenue:

Management fees $1,161,180

Grants 1,067,577

Royalty-related party 45,238

Total revenue 2,273,995

Expenses:

Research and development 89,669,281

Contracted research and

development-related party 7,980,299

Selling, general and administrative 25,169,667

Total expenses 122,819,247

Loss from operations (120,545,252)

Net other (income) expense:

Interest income (2,926,346)

Interest expense 2,933,446

Gain on sale of interest in Sarawak

Medichem Pharmaceuticals joint

venture (939,052)

Net other (income) expense (931,952)

Net loss (119,613,300)

Less accumulated preferred stock

dividends of subsidiary for the

period 1,626,042

Net loss available to common

shareholders $(121,239,342)

Net loss per share available to

common shareholders - basic and

diluted

Weighted average shares outstanding -

basic and diluted


'/>"/>
SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Advanced Cell Technology Announces Proposed Financing
4. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
7. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System
10. NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
11. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... NOVATO, Calif. , May 21, 2015 /PRNewswire-USNewswire/ ... Orrin Hatch (R-UT) and Amy ... Product Extensions Now Accelerating Cures & Treatments, or ... 150 rare disease patient advocacy organizations, this bipartisan ... effective, and affordable medicines to rare disease patients ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Kingston, Ontario (PRWEB) May 21, 2015 ... entered into an exclusive North American distribution agreement ... microbiology testing system. , With more than 160 ... of products and services for laboratory and production ... choice, operational excellence and differentiated services to enable ...
(Date:5/20/2015)... MA (PRWEB) May 20, 2015 This ... history, especially for lawns. US Patented Pearl’s Premium ... for lawns around the country that are coming out ... that addresses a number of major global concerns related ... the “non-grass” grass – the alternative to the standard, ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2
... report commissioned by the U.S. Department of Energy has ... of producing hydrogen fuel from sunlight is the only ... meet future cost targets set by the federal agency. ... Alan Weimer,s research team of CU-Boulder,s chemical and biological ...
... Stem Cell Assurance, Inc. (SCLZ.PK) announced today ... Securities on Form 10 pursuant to Section 12(g) of the ... financial statements as of December 31, 2009 and 2010 and ... July 11, 2011, the Company will become an SEC reporting ...
... Dan Neumeister, FACHE, principal of Neumeister Healthcare Management Services ... selected by Chase Brexton Health Services (CBHS) of Baltimore, ... effective May 1, 2011. Neumeister is serving in this ... fills the position. As CBHS,s top ...
Cached Biology Technology:CU method projected to meet DOE cost targets for solar thermal hydrogen fuel production 2Regional Healthcare Management Firm Goes National 2
(Date:5/21/2015)... 2015 According to a ... (Hardware, Software, Services), by Applications (Surveillance (Airborne, Maritime, ... End-Users (Military & Defense & Commercial) - Global ... Market is expected to grow from $7252.0 Million ... a Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... subsidiary, 3D-ID LLC, a company engaged in biometric identification ... biometrics technology portion of the recently awarded TIES (Technical ... of the Army. 3D-ID LLC has a ... law enforcement and security agencies. Gino ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2
... to drugs, alcohol and tobacco in utero is bad ... have been hard to tease out in humans. Often ... factors like poverty can also influence brain development. ... brain scans, led by Childrens Hospital Boston neurologist Michael ...
... scientists are now flying through springtime Arctic pollution to ... summertime sea ice is melting - faster than predicted. ... university colleagues in Fairbanks, Alaska, to conduct the study ... our eyes, said A.R. Ravishankara, director of the chemistry ...
... Endometriosis is a poorly understood condition that incapacitates and affects ... world. In the US, it affects approximately six million women ... year. It is a chronic painful disease which occurs ... in the area of the ovaries and fallopian tubes, but ...
Cached Biology News:Your baby's brain on drugs (and alcohol and tobacco) 2NOAA aircraft to probe arctic pollution 2New study finds uncontrollable stress worsens symptoms of endometriosis 2New study finds uncontrollable stress worsens symptoms of endometriosis 3
This adapter allows the Thermo-Fast® 96 Semi-Skirted (AB-0900 and AB-0990) PCR plates to be used directly in the ABI PRISM® 3100 sequencer without the need for software changes....
... pleased to offer the ATTO-TAG series ... of primary amines. Developed by Novotny ... ATTO-TAG reagents are similar to the ... and anthracene-2,3-dicarboxaldehyde, all of which are ...
...
... pleased to offer the ATTO-TAG series ... of primary amines. Developed by Novotny ... ATTO-TAG reagents are similar to the ... and anthracene-2,3-dicarboxaldehyde, all of which are ...
Biology Products: